Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf multimodal viral immunotherapies for solid tumors. Its platforms are designed to cause in-situ immunization by inducing tumor cell lysis and stimulating both innate and adaptive immune responses. Candel's investigational therapies target durable clinical benefit across multiple cancer indications, including prostate cancer, lung cancer, and glioblastoma.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountUnknown
Feb 2026
Jan 2024
Jul 2021
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...
